Loading...
Market
Main competitor to Novo Nordisk in cardiovascular diabetes market by end of 2025?
2
Resolution / Starting Odds
Eli Lilly • 25%
Sanofi • 25%
AstraZeneca • 25%
Other • 25%
Industry reports and market share analysis
Story
Novo Nordisk's Rybelsus Cuts Cardiovascular Risk by 14% in SOUL Trial
Oct 21, 2024, 10:15 AM
Novo Nordisk's oral semaglutide, marketed as Rybelsus, has demonstrated a 14% reduction in the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes, according to the results of the SOUL trial. The late-stage study, announced on Monday, involved over 9,600 patients with type 2 diabetes and heart or kidney disease. Novo Nordisk plans to file for regulatory approval of a label expansion for Rybelsus in both the US and EU around the turn of the year. The drug, a tablet version of Ozempic, showed significant potential in reducing the risk of heart attacks and strokes, which may drive broader use of the medication.
View original story
Similar markets
Novo Nordisk • 25%
Eli Lilly • 25%
Pfizer • 25%
Other • 25%
Semaglutide • 25%
Empagliflozin • 25%
Dapagliflozin • 25%
Other • 25%
Increase by over 5% • 25%
Increase by 1-5% • 25%
No significant change • 25%
Decrease • 25%
Leader in the sector • 25%
Top 3 in the sector • 25%
Top 5 in the sector • 25%
Outside top 5 • 25%
Wegovy • 25%
Zepbound • 25%
Ozempic • 25%
Other • 25%
Novo Nordisk • 25%
Sanofi • 25%
Eli Lilly • 25%
Other • 25%
Significantly increase • 25%
Slightly increase • 25%
No change • 25%
Decrease • 25%
Top 5 • 25%
Top 10 • 25%
Top 20 • 25%
Below Top 20 • 25%
Focus on improving CagriSema • 25%
Develop a new obesity drug • 25%
Increase investment in marketing existing drugs • 25%
Pursue mergers or acquisitions • 25%
Top 5 • 25%
Top 10 • 25%
Top 20 • 25%
Below Top 20 • 25%